section name header

Pronunciation

ral-TEG-ra-veer

Classifications

Therapeutic Classification: antiretrovirals

Pharmacologic Classification:

Indications

REMS

Action

Therapeutic Effects:

Pharmacokinetics

Absorption: Well absorbed following oral administration.

Distribution: Unknown.

Metabolism/Excretion: Mostly metabolized by the uridine diphosphate glucuronosyltransferase (UGT) A1A enzyme system; 23% excreted in urine as parent drug and metabolite.

Half-life: 9 hr.

Time/Action Profile

(plasma concentrations)

ROUTEONSETPEAKDURATION
POunknown3 hr12 hr

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: MI.

Derm: rash, STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS.

GI: diarrhea, abdominal pain, gastritis, hepatitis, nausea, vomiting.

GU: renal failure/impairment.

Hemat: anemia, neutropenia.

Metab: lipodystrophy.

MS: creatine kinase, myopathy, RHABDOMYOLYSIS.

Neuro: headache, depression, dizziness, fatigue, insomnia, SUICIDAL THOUGHTS, weakness.
Misc: fever, immune reconstitution syndrome.

Interactions

Drug-Drug:

Route/Dosage

Do not substitute the chewable tablets or oral suspension for the film-coated tablets.

Availability

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Isentress, Isentress HD